ACIU - ACイミュ―ン (AC Immune SA) ACイミュ―ン

 ACIUのチャート


 ACIUの企業情報

symbol ACIU
会社名 AC Immune SA (ACイミュ―ン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases such as Down syndrome glaucoma and Parkinson''s and focuses on producing therapeutic and diagnostic product candidates using SupraAntigen and Morphomer technology platforms. The Company''s pipeline includes Crenezumab ACI-24 Anti-Tau antibody Morphomer Tau Tau-PET imaging agent Morphomer Abeta and Morphomer alpha-syn among others.   ACイミュ―ンはスイスのバイオ医薬品企業。臨床段階で、細胞内のタンパク質の折りたたみ異常に起因する神経変性疾患の特定や治療薬の開発に従事する。広範囲の神経変性疾患を対象にパ―キンソン病、ダウン症、緑内障の予防や診断、治療に対応するために抗体や小分子、ワクチンを作成する。本社はラウサネ。   AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in Precision Medicine for neurodegenerative diseases. The Company is utilizing two proprietary discovery platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials. It has collaborations with major pharmaceutical companies including Roche/Genentech, Lilly and Janssen.
本社所在地 EPFL Innovation Park Building B Lausanne 1015 CHE
代表者氏名 Martin Velasco マーティンベラスコ
代表者役職名 Chairman of the Board of Directors
電話番号 +41 21-345-9121
設立年月日 37653
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数
url www.acimmune.com
nasdaq_url https://www.nasdaq.com/symbol/aciu
adr_tso
EBITDA EBITDA(百万ドル) -28.79702
終値(lastsale) 7.35
時価総額(marketcap) 495115771.5
時価総額 時価総額(百万ドル) 527.14420
売上高 売上高(百万ドル) 21.15660
企業価値(EV) 企業価値(EV)(百万ドル) 424.17964
当期純利益 当期純利益(百万ドル) -27.61319
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AC Immune SA revenues increased 26% to SF3.5M. Net loss increased 4% to SF22.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Operating Expense - R&D increase of 57% to SF15.2M (expense) Labor_Related Expenses in R&D increase from SF2.2M to SF5.4M (expense).

 ACIUのテクニカル分析


 ACIUのニュース

   Alzheimer''s Drugs Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report  2021/07/14 08:33:02 Benzinga
Pune, India, July 14, 2021 (GLOBE NEWSWIRE) -- Increasing prevalence of Alzheimer''s disease is fueling the demand for Alzheimer''s drugs which in turn is driving the global Alzheimer''s drugs market, says Fortune Business Insights in a report, titled " Alzheimer''s Drugs Market ", Size, Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026. Rising R&D activities by pharmaceutical companies and research institutes for Alzheimer effective therapy is expected to boost the global Alzheimer''s drugs market. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alzheimers-drugs-market-101033 The report covers: Global Alzheimer''s Drugs Market trends, with detailed analysis on consumer trends & manufacturer trends. Overview on supply analysis covering trends across raw material suppliers, technology providers and distributors.
   Eli Lilly and Company Consensus Indicates Potential .5% Upside  2021/07/08 12:16:42 DirectorsTalk
Eli Lilly and Company found using ticker (LLY) now have 19 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 300 and 190 calculating the average target price we see 236.68. With the stocks previous close at 235.42 this would indicate that there is a potential upside of .5%. The 50 day moving average now sits at 216.62 and the 200 moving average now moves to 197.22. The company has a market cap of $226,157m. Visit the company website at: /> [stock_market_widget type="chart" symbol="LLY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
   AC Immune Holds its Annual General Meeting of Shareholders  2021/06/25 12:38:00 Intrado Digital Media
LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders.
   Here are the 9 biggest biotech winners after the FDA took an entirely new approach to approve Biogen''s Alzheimer''s drug  2021/06/08 12:00:37 Business Insider
Summary List Placement In spending more than $2 billion researching Alzheimer''s disease treatments, the biotech giant Biogen made a risky bet. Rivals have racked up failure after failure in the space. That bet paid off on Monday, when the Food and Drug Administration approved its Alzheimer''s drug, called Aduhelm. The approval itself, as well as the new and controversial approach that the FDA took to greenlight the drug, is reigniting interest in Alzheimer''s research, sending the stock of Biogen and other biotechs soaring. The decision signals that it may be easier to get drugs for neurologic disorders like Alzheimer''s approved in the future. "In our view, FDA neuro division is becoming more flexible, supportive and conducive in getting neurology drugs approved, as evidenced by today''s approval as well as the FDA''s favorable comments during Biogen''s advisory committee meeting," Jefferies analyst Andrew Tsai wrote in a note. "We envision investor appetite to rise in Alzheimer''s as a whole." Aduhelm is the first drug to hit the market that targets amyloid beta, a sticky plaque that builds up in the brains of some Alzheimer''s disease patients and is thought to impair memory and cognition.
   AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates  2021/06/02 12:44:54 Seeking Alpha
   Recap: AC Immune Q4 Earnings  2021/03/23 08:01:00 Benzinga
Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per …
   Why Can-Fite, Moderna, AC Immune Shares Are Rallying  2021/03/16 10:52:00 Benzinga
Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday. Moderna …
   AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference  2021/02/17 12:00:00 Yahoo Finance
LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 22–26, 2021. During a fireside chat, AC Immune CEO Prof. Andrea Pfeifer will discuss the Company’s execution strategy to advance and accelerate its precision medicine approach to targeting neurodegenerative diseases. Prof. Pfeifer will also highlight AC Immune’s novel anti-phospho-Tau (pTau) vaccine candidate ACI-35.030, including recent interim Phase 1b/2a results that showed promising immunogenicity and safety in patients with early Alzheimer’s disease. AC Immune is developing ACI-35.030 in collaboration with its strategic partner Janssen Pharmaceuticals, Inc. SVB Leerink 10th Annual Global Healthcare ConferenceDate: February 24, 2020 | 11:20–11:50 am ET / 5:20–5:50 pm CETFormat: Fireside chatPresenter: Prof.
   AC Immune has 'remarkable' Alzheimer's vaccine data. Just don't ask to see them  2021/02/11 15:33:56 Endpoints News
AC Immune announced it has
   AC Immune: Q3 Earnings Insights  2020/11/13 07:27:00 Benzinga
Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% …
   AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference  2021/02/17 12:00:00 Yahoo Finance
LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 22–26, 2021. During a fireside chat, AC Immune CEO Prof. Andrea Pfeifer will discuss the Company’s execution strategy to advance and accelerate its precision medicine approach to targeting neurodegenerative diseases. Prof. Pfeifer will also highlight AC Immune’s novel anti-phospho-Tau (pTau) vaccine candidate ACI-35.030, including recent interim Phase 1b/2a results that showed promising immunogenicity and safety in patients with early Alzheimer’s disease. AC Immune is developing ACI-35.030 in collaboration with its strategic partner Janssen Pharmaceuticals, Inc. SVB Leerink 10th Annual Global Healthcare ConferenceDate: February 24, 2020 | 11:20–11:50 am ET / 5:20–5:50 pm CETFormat: Fireside chatPresenter: Prof.
   AC Immune has 'remarkable' Alzheimer's vaccine data. Just don't ask to see them  2021/02/11 15:33:56 Endpoints News
AC Immune announced it has
   AC Immune: Q3 Earnings Insights  2020/11/13 07:27:00 Benzinga
Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% …
   FXNEWS24 |Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline | UK Forex Reviews  2020/11/04 18:17:21 FXNews24
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Global Down syndrome market Is Projected To Witness Vigorous Expansion By 2026 | OPKO Health, Inc., LuMind IDSC Foundation, MIT Alana Center, H. Lundbeck A/S, AC Immune  2020/10/07 20:40:58 OpenPR
Global Down Syndrome Market research report has been prepared with a nice combination of industry insight, smart solutions, practical solutions and newest technology to give better user experience. Under market segmentation chapter, research and analysis is done based on several

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ACイミュ―ン ACIU AC Immune SA)

 twitter  (公式ツイッターやCEOツイッターなど)